Your browser doesn't support javascript.
loading
Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
Lewnard, Joseph A; Charani, Esmita; Gleason, Alec; Hsu, Li Yang; Khan, Wasif Ali; Karkey, Abhilasha; Chandler, Clare I R; Mashe, Tapfumanei; Khan, Ejaz Ahmed; Bulabula, Andre N H; Donado-Godoy, Pilar; Laxminarayan, Ramanan.
Afiliação
  • Lewnard JA; Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA. Electronic address: jlewnard@berkeley.edu.
  • Charani E; Division of Infectious Diseases & HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Gleason A; One Health Trust, Bengaluru, India; High Meadows Environmental Institute, Princeton University, Princeton, NJ, USA.
  • Hsu LY; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
  • Khan WA; International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
  • Karkey A; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
  • Chandler CIR; Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK; Antimicrobial Resistance Centre, London School of Hygiene & Tropical Medicine, London, UK.
  • Mashe T; One Health Office, Ministry of Health and Child Care, Harare, Zimbabwe; Health System Strengthening Unit, WHO, Harare, Zimbabwe.
  • Khan EA; Department of Pediatrics, Shifa Tameer-e-Millat University, Shifa International Hospital, Islamabad, Pakistan.
  • Bulabula ANH; Division of Disease Control and Prevention, Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.
  • Donado-Godoy P; AMR Global Health Research Unit, Colombian Integrated Program of Antimicrobial Resistance Surveillance, Corporación Colombiana de Investigación Agropecuaria, Cundinamarca, Colombia.
  • Laxminarayan R; One Health Trust, Bengaluru, India; High Meadows Environmental Institute, Princeton University, Princeton, NJ, USA. Electronic address: ramanan@onehealthtrust.org.
Lancet ; 403(10442): 2439-2454, 2024 Jun 01.
Article em En | MEDLINE | ID: mdl-38797180
ABSTRACT
National action plans enumerate many interventions as potential strategies to reduce the burden of bacterial antimicrobial resistance (AMR). However, knowledge of the benefits achievable by specific approaches is needed to inform policy making, especially in low-income and middle-income countries (LMICs) with substantial AMR burden and low health-care system capacity. In a modelling analysis, we estimated that improving infection prevention and control programmes in LMIC health-care settings could prevent at least 337 000 (95% CI 250 200-465 200) AMR-associated deaths annually. Ensuring universal access to high-quality water, sanitation, and hygiene services would prevent 247 800 (160 000-337 800) AMR-associated deaths and paediatric vaccines 181 500 (153 400-206 800) AMR-associated deaths, from both direct prevention of resistant infections and reductions in antibiotic consumption. These estimates translate to prevention of 7·8% (5·6-11·0) of all AMR-associated mortality in LMICs by infection prevention and control, 5·7% (3·7-8·0) by water, sanitation, and hygiene, and 4·2% (3·4-5·1) by vaccination interventions. Despite the continuing need for research and innovation to overcome limitations of existing approaches, our findings indicate that reducing global AMR burden by 10% by the year 2030 is achievable with existing interventions. Our results should guide investments in public health interventions with the greatest potential to reduce AMR burden.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacorresistência Bacteriana / Países em Desenvolvimento Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacorresistência Bacteriana / Países em Desenvolvimento Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2024 Tipo de documento: Article